GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
- PMID: 37108703
- PMCID: PMC10139115
- DOI: 10.3390/ijms24087541
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Abstract
Most kinase inhibitors are designed to bind to highly homologous ATP-binding sites, which leads to promiscuity and possible off-target effects. Allostery is an alternative approach to pursuing selectivity. However, allostery is difficult to exploit due to the wide variety of underlying mechanisms and the potential involvement of long-range conformational effects that are difficult to pinpoint. GSK-3β is involved in several pathologies. This critical target has an ATP-binding site that is highly homologous with the orthosteric sites of other kinases. Unsurprisingly, there is also great similarity between the ATP-binding sites of GSK-3β and its isomer, which is not redundant and thus would benefit from selective inhibition. Allostery would also allow for a moderate and tunable inhibition, which is ideal for GSK-3β, because this target is involved in multiple pathways, some of which must be preserved. However, despite considerable research efforts, only one allosteric GSK-3β inhibitor has reached the clinic. Moreover, unlike other kinases, there are no X-ray structures of GSK-3β in complex with allosteric inhibitors in the PDB data bank. This review aims to summarize the state of the art in allosteric GSK-3β inhibitor investigations, highlighting the aspects that make this target challenging for an allosteric approach.
Keywords: Alzheimer’s disease; Pocketron; cancer; drug discovery; inhibitors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays.Int J Mol Sci. 2022 Mar 31;23(7):3856. doi: 10.3390/ijms23073856. Int J Mol Sci. 2022. PMID: 35409221 Free PMC article.
-
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26. Biomed Pharmacother. 2020. PMID: 32470749
-
Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. doi: 10.1016/j.bmcl.2012.09.043. Epub 2012 Sep 23. Bioorg Med Chem Lett. 2012. PMID: 23099099
-
Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease.Adv Pharm Bull. 2023 Nov;13(4):688-700. doi: 10.34172/apb.2023.071. Epub 2023 Jan 23. Adv Pharm Bull. 2023. PMID: 38022801 Free PMC article. Review.
-
Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.Curr Drug Metab. 2018;19(8):663-673. doi: 10.2174/1389200219666171227203737. Curr Drug Metab. 2018. PMID: 29283064 Review.
Cited by
-
Connecting GSK-3β Inhibitory Activity with IKK-β or ROCK-1 Inhibition to Target Tau Aggregation and Neuroinflammation in Alzheimer's Disease-Discovery, In Vitro and In Cellulo Activity of Thiazole-Based Inhibitors.Molecules. 2024 Jun 2;29(11):2616. doi: 10.3390/molecules29112616. Molecules. 2024. PMID: 38893493 Free PMC article.
-
Endocrine Disrupting Toxicity of Bisphenol A and Its Analogs: Implications in the Neuro-Immune Milieu.J Xenobiot. 2025 Jan 17;15(1):13. doi: 10.3390/jox15010013. J Xenobiot. 2025. PMID: 39846545 Free PMC article. Review.
-
Targeting Canonical Wnt-signaling Through GSK-3β in Arrhythmogenic Cardiomyopathy: Conservative or Progressive?J Cardiovasc Transl Res. 2025 Feb;18(1):121-132. doi: 10.1007/s12265-024-10567-x. Epub 2024 Oct 11. J Cardiovasc Transl Res. 2025. PMID: 39392548 Free PMC article. Review.
-
A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases.Cent Nerv Syst Agents Med Chem. 2024;24(3):294-303. doi: 10.2174/0118715249289120240321065936. Cent Nerv Syst Agents Med Chem. 2024. PMID: 38646682 Review.
-
Modulation of Wnt/Beta-Catenin Pathway by Major Dietary Phytochemicals Against Breast Cancer Development.Biology (Basel). 2025 Feb 13;14(2):194. doi: 10.3390/biology14020194. Biology (Basel). 2025. PMID: 40001961 Free PMC article. Review.
References
-
- Amar S., Belmaker R.H., Agam G. The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases. Curr. Pharm. Des. 2011;17:2264–2277. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources